Drug Trial Radar · NCT07151872
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase II clinical study aimed at evaluating the efficacy, safety, PK profile, and immunogenicity of QLS31905 for Injection combined with Chemotherapy ± QL2107 in Patients with CLDN18.2-positive Advanced Biliary Tract Cancer
Conditions
- CLDN18.2-positive Advanced Biliary Tract Cancer
Interventions
QLS31905 for InjectionDrug
QLS31905 for Injection
Gemcitabine Hydrochloride for InjectionDrug
Gemcitabine Hydrochloride for Injection
Cisplatin for InjectionDrug
Cisplatin for Injection
QL2107 InjectionDrug
QL2107 Injection
Oxaliplatin InjectionDrug
Oxaliplatin Injection
Capecitabine TabletsDrug
Capecitabine Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (Objective Response Rate)Time frame: Approximately 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.